Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry

Elisa Gremese, Gianfranco Ferraccioli, Luca Iaccarino, Elena Bartoloni, Linda Carli, Fulvia Ceccarelli, Fabrizio Conti, Salvatore De Vita, Mauro Galeazzi, Mariele Gatto, Roberto Gerli, Marcello Govoni, Annamaria Iuliano, Elena Mansutti, Gabriella Moroni, Marta Mosca, Cecilia Nalli, Carla Naretto, Melissa Padovan, Lavinia PalmaFrancesca Raffiotta, Dario Roccatello, Angela Tincani, Guido Valesini, Margherita Zen, Andrea Doria

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

To evaluate the efficacy and safety of rituximab (RTX) in patients with systemic lupus erythematosus (SLE) refractory to standard therapy in the clinical practice setting.
Original languageEnglish
Pages (from-to)449-456
Number of pages8
JournalCLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Volume33
Publication statusPublished - 2015

Keywords

  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Drug Resistance
  • Immunosuppression
  • Lupus Erythematosus, Systemic
  • Middle Aged
  • Off-Label Use
  • Remission Induction
  • Rituximab
  • Severity of Illness Index
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry'. Together they form a unique fingerprint.

Cite this